The Expression of Zinc Finger E-Box Binding Homeobox 1 (ZEB1) in Circulating Tumor Cells(CTCs) Associated With Metastasis and Recurrence for Gastric Cancer
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 100
- 主要终点
- three-year disease free survival rate
研究概览
简要总结
The aim of this study was to investigate the expression of ZEB1 in CTCs for gastric cancer, its correlation with the clinicopathology of gastric cancer, and the role of ZEB1 in invasion and metastasis in gastric cancer.
详细描述
Invasion and metastasis of tumors and postoperative recurrence are the main causes of death in patients with gastric cancer and are also the key factors affecting the clinical treatment and prognosis.
In this study, the investigators will detect the expression of ZEB1 in different types of CTCs(epithelial,mesenchymal and mixed phenotype) for gastric cancer by CanPatrolTM2 detection technology.Our investigation of the relationship between ZEB1 and the occurrence and development as well as the invasion and metastasis of gastric cancer is expected to provide data for the prognosis and targeted therapy of gastric cancer.
Approximate 100 consecutive patients with gastric cancer and CTCs(+) will be enrolled in this study.Detection of ZEB1 expression in CTCs at baseline will show the relationship between ZEB1 and clinicopathological variables. Postoperative follow-up of ZEB1 expression in CTCs will be performed every three months in the first year and every six months in the following two years. The results may indicate the role of ZEB1 in CTCs about invasion and metastasis for gastric cancer .The aim of this study is to clarify the clinical significance of ZEB1 expression in CTCs for gastric cancer.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologically proven gastric cancer and CTCs(+).
- •Age:older than 18 years old,younger than 80 years old.
- •cT1-4a(surgically resectable tumor),N0-3,M0 at preoperative evaluation according to the American Joint Committee on Cancer(AJCC) Cancer Staging Manual Seventh Edition.
- •No obvious surgical contraindications.
- •American Society of Anesthesiology (ASA) score class I, II, or III.
- •Written informed consent.
排除标准
- •Severe mental disorder.
- •History of previous gastrectomy,endoscopic mucosal resection or endoscopic submucosal dissection.
- •History of unstable angina or myocardial infarction within past six months.
- •History of previous neoadjuvant chemotherapy or radiotherapy.
- •History of other malignant disease within past 5 years.
结局指标
主要结局
three-year disease free survival rate
时间窗: Up to 3 years post-operative
次要结局
- baseline detection of ZEB1 expression(1 year)
- three-year overall survival rate(Up to 3 years post-operative)
- metastasis and recurrence rate(Up to 3 years post-operative)
研究者
wei bo
Vice Director of the general surgery department, Chinese PLA General Hospital
Chinese PLA General Hospital